To cut costs and help extend its cash runway into 2028, ADC Therapeutics is laying off about 30% of its global workforce, closing its U.K. research facility and trimming its pipeline, the company announced June 12. The Switzerland-based biotech had 265 employees as of Dec. 31, according to its annual report, meaning the layoffs could affect around 80 employees.
